No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.
Novo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs for diabetes patients in the US through a text messaging pilot.
Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.